

Plus Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Business Highlights

February 22, 2021

- Positive interim data through cohort five for the ReSPECT™ Phase 1 clinical trial in recurrent glioblastoma, announced November 2020 -

- Completed sixth dosing cohort in ReSPECT™ December 2020 -

- Management to host conference call today, Monday, February 22 nd, at 5:00 p.m. ET -

AUSTIN, Texas, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing novel, targeted therapies for rare and difficult to treat cancers, today announced financial results for the fourth quarter and full year ended December 31, 2020, and provided an overview of recent business highlights.

"In the second quarter of 2020, we in-licensed a promising new radiotherapeutic platform and portfolio of investigational drugs, then made substantial clinical progress for the lead compound and also moved additional opportunities closer to clinical phase," said Marc Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics. "In 2021, we intend to make even greater progress advancing our CNS oncology portfolio through the development process and bringing it closer to a potential registrational clinical trial read out."

Rhenium NanoLiposome (RNL™) Program - Background and 2020 Highlights

The Company's lead investigational drug is RNL™, a radiotherapy in development for several rare cancer targets, including recurrent glioblastoma (GBM) in the U.S. multi-center ReSPECT™ Phase 1 dose-finding trial. RNL™ is designed to safely, effectively, and conveniently deliver a very high dose of radiation directly into the brain tumor compared to traditional external beam radiation therapy (EBRT). 2020 highlights for RNL™ include:

- ReSPECTTM trial of RNLTM for recurrent glioblastoma supported by a multi-phase and multi-year financial grant from the U.S. National Institutes of Health/National Cancer Institute (NIH/NCI).
- RNL[™] received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration (FDA) for the treatment of GBM.
- Presented positive interim data from the first 15 patients, through Cohort 5, in the ReSPECT[™] trial at the 2020 Society for Neuro-Oncology Annual Meeting (SNO 2020 E-poster).
- Completed the 6th dose escalation cohort, with 18 total patients treated in ReSPECT[™], with increases in both the RNL[™] drug volume and radiation dose.
- Thus far, RNL[™] can be successfully delivered with up to 15 times the absorbed dose of radiation administered by standard EBRT without significant toxicity.
- ReSPECT[™] clinical trial expanded to two additional locations.
- Established Clinical Advisory and Scientific Advisory Boards with leading experts in the fields of neurosurgery, neuro-oncology, preclinical drug development, and nanotechnology.

Expected Upcoming Milestones and Events

In upcoming quarters, the Company intends to focus on a number of additional business objectives and potential milestones:

- Complete enrollment of the ReSPECT™ Phase 1 trial for RNL™ in recurrent glioblastoma
- Complete pivotal trial planning with FDA for RNL™ in recurrent glioblastoma.
- Complete pre-IND meeting with the FDA, execute IND-enabling studies, if needed, and move into clinical trials for follow-on RNL[™] indications, leptomeningeal metastases and pediatric brain cancer.
- Continue development and evaluation of additional external and internal drug development candidates to expand the pipeline.
- Continue partnership discussions for three clinical-stage injectable drugs: RNL™, DocePLUS™, and generic DoxoPLUS™

Fourth Quarter 2020 Financial Results

■ As of December 31, 2020, the Company's cash balance was \$8.3 million, compared to \$17.6 million as of December 31, 2019.

- Net cash used in operating activities was \$8.4 million for the year ended December 31, 2020, compared to net cash used in operating activities of \$5.9 million during the same period in 2019.
- During the second quarter of 2020, \$5.0 million of the Oxford debt principal was paid down to a current principal balance of \$4.3 million at December 31, 2020.
- Net loss for full year 2020 was \$8.2 million, or \$(1.86) per share, compared to a net loss of \$11.4 million, or \$(8.27) per share (on a fully diluted basis including preferred stock), for full year 2019.

Conference Call

The Company will hold a conference call and live audio webcast at 5:00 p.m. Eastern Time today to discuss its financial results and provide a general business update.

Event: Plus Therapeutics Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast

Date: Monday, February 22, 2021 Time: 5:00 p.m. Eastern Time

Live Call: 877-402-3914 (toll free); 631-865-5294 (Intl.); Conference ID: 6206747

The webcast can be accessed live via the investor section of the Plus Therapeutics website at <u>ir.plustherapeutics.com/events</u> and will be available for replay beginning two hours after the conclusion of the conference call.

About Plus Therapeutics, Inc.

Plus Therapeutics (Nasdaq: PSTV) is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets. Central to the Company's drug development is a unique nanotechnology platform designed to reformulate, deliver and commercialize multiple drugs targeting rare cancers and other diseases. The platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers. More information may be found at www.PlusTherapeutics.com and www.respect-trials.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains statements that may be deemed "forward-looking statements" within the meaning of U.S. securities laws. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as "will," "believe," "plan," "can," "enable," "design," "intend," "potential," "expect," "estimate," "project," "prospect," "target," "focus," "anticipate," "could," "should," and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the design and potential of the Plus Therapeutics portfolio to reformulate, deliver and commercialize multiple novel, proprietary drugs targeting rare cancers and other diseases and to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs; the potential of the Company's new, in-licensed portfolio of investigational drugs; the Company's intent to advance its CNS oncology portfolio through the clinical development process; the ability of RNL to safely, effectively and conveniently deliver a very high dose of radiation greater than traditional EBRT directly into the brain tumor; and the Company's anticipated milestones and events, including with respect to enrollment, pivotal trial planning, IND process, and clinical phase plans for RNL, pipeline expansion through additional drug development candidates, and partnership discussions for RNL, DocePLUS and DoxoPLUS. The forward-looking statements included in this press release are subject to a number of risks and uncertainties that may cause actual results to differ materially from those discussed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that the Company is not able to successfully develop product candidates that can leverage the U.S. FDA's accelerated regulatory pathways; the early stage of the Company's product candidates and therapies, the results of its research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company's history of losses; the Company's need for, and ability to raise, additional cash or obtain other sources of funding in the immediate future; the Company's ability to: (a) obtain and maintain regulatory approvals, (b) continue as a going concern, (c) remain listed on the Nasdaq Capital Market, (d) to obtain or maintain sufficient levels of reimbursement for its tests, and (d) to repay or refinance some or all of its outstanding indebtedness; the outcome of the Company's partnering/licensing efforts; market and economic conditions; the impact of the COVID-19 pandemic on the Company and the effectiveness of the efforts it has taken or may take in the future in response thereto; and additional risks described under the heading "Risk Factors" in the Company's Securities and Exchange Commission filings, including in the Company's annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.

PLUS THERAPEUTICS, INC. CONSOLIDATED BALANCE SHEETS (in thousands, except share and par value data)

	 As of December 31,			
	2020		2019	
Assets				
Current assets:				
Cash and cash equivalents	\$ 8,346	\$	17,552	

Accounts receivable		_		1,169
Restricted cash		_		40
Inventories, net		_		107
Other current assets		829		957
Total current assets		9,175		19,825
Property and equipment, net		1,820		2,179
Operating lease right-use-of assets		636		781
Goodwill		372		372
Intangible assets, net		86		_
Other assets		16		72
Total assets	\$	12,105	\$	23,229
Liabilities and Stockholders' Equity				
Current liabilities:				
Accounts payable and accrued expenses	\$	2,081	\$	3,279
Operating lease liability		123		147
Term loan obligation, net of discount		6,335		11,060
Total current liabilities		8,539		14,486
Noncurrent operating lease liability		528		646
Warrant liability		7		6,929
Other noncurrent liabilities		<u> </u>		8
Total liabilities		9,074		22,069
Commitments and contingencies				
Stockholders' equity:				
Preferred stock, \$0.001 par value; 5,000,000 shares authorized; 1,954 and 1,959 shares issued and outstanding in 2020 and 2019, respectively		_		_
Common stock, \$0.001 par value; 100,000,000 shares authorized; 6,749,028 and 3,880,588 shares issued and outstanding in 2020 and 2019, respectively		7		4
Additional paid-in capital		436,535		426,426
Accumulated deficit		(433,511)		(425,270)
Total stockholders' equity		3,031		1,160
Total liabilities and stockholders' equity	\$	12,105	\$	23,229
	*	,	*	-,

PLUS THERAPEUTICS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (in thousands, except share and per share data)

	For the Years En	For the Years Ended December 31,		
	2020	2019		
Development revenue:				
Government contracts and other	\$ 303	\$ 6,998		
	303	6,998		
Operating expenses:				
Research and development	2,700	5,365		
In process research and development acquired from NanoTx	781	_		
General and administrative	6,406	5,290		
Total operating expenses	9,887	10,655		
Operating loss	(9,584)	(3,657)		
Other income (expense):				
Interest income	50	55		
Interest expense	(1,107)	(1,855)		
Change in fair value of liability instruments	2,400	3,407		
Issuance cost of warrants		(1,233)		
Total other expense	1,343	374		
Loss from continuing operations	\$ (8,241)	\$ (3,283)		

Loss from discontinued operations	_	(7,604)
Net loss	\$ (8,241)	\$ (10,887)
Loss from continuing operations	\$ (8,241)	\$ (3,283)
Beneficial conversion feature for convertible preferred stock	 	 (554)
Net loss allocable to common stockholders - continuing operations	\$ (8,241)	\$ (3,837)
Net loss allocable to common stockholders - discontinued operations	 	 (7,604)
Net loss allocable to common stockholders	\$ (8,241)	\$ (11,441)
Basic and diluted net loss per share attributable to common stockholders – continuing operations	\$ (1.86)	\$ (2.77)
Basic and diluted net loss per share attributable to common stockholders - discontinued operations	 	 (5.49)
Net loss per share, basic and diluted	\$ (1.86)	\$ (8.27)
Basic and diluted weighted average shares used in calculating net loss per share	4 407 005	4 204 040
attributable to common stockholders	4,427,835	1,384,012

PLUS THERAPEUTICS, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands)

For the Years Ended December 31,

Cash flows used in operating activities: 5 (8,24) \$ (10,87) Cash stream to reconcile net loss to net cash used in operating activities: 8 (8,24) \$ (10,87) Depreciation and amoritzation 366 866 Amoritzation of deferred financing costs and debt discount 584 550 Change in fair value of liability instruments (2,40) (3,407) Change in fair value of liability instruments (2,40) (3,407) Change in fair value of liability instruments (2,40) (3,407) Change in fair value of liability instruments (2,40) (3,407) Change in fair value of liability instruments (2,40) (3,407) Change in fair value of liability instruments (2,40) (3,207) Noncash lease expense (3,10) (2,20) Allocation of issuance cost associated with warrants (3,10) (2,20) Allocation of issuance cost associated with warrants (3,10) (2,20) Allocation of issuance cost associated with warrants (3,10) (2,20) Accounts receivable (3,10) (2,20) Obten current assets (3,20) (2,20)		FOL	FOI THE TEATS ETILLED DECETION 31		
Net loss (8,241) (10,8787) Adjustments to reconcile net loss to net cash used in operating activities: 366 896 Depreciation and amortization 366 896 Amortization of deferred financing costs and debt discount 584 550 In process research and development acquired from NanoTx Therapeutics (2,400) (3,407) Change in fair value of liability instruments 247 127 Inventory write off 3 12 Noncash lease expense 3 12 Loss on sale of business 3 12 Allocation of issuance cost associated with warrants			2020		2019
Adjustments to reconcile net loss to net cash used in operating activities: 366 896 Depreciation and amortization 366 550 Amortization of deferred financing costs and debt discount 564 550 In process research and development acquired from NanoTx Therapeutics 781 — Change in fair value of liability instruments (2,400) (3,407) Share-based compensation expense 247 127 Inventory write off 107 — Noncash lease expense 3 12 Loss on sale of business 3 12 Loss on sale of business — 6,508 Allocation of issuance cost associated with warrants — 6,508 Increases (decreases) in cash caused by changes in operating assets and liabilities — 2,509 Increases (decreases) in cash caused by changes in operating assets and liabilities 1,169 (1,203) Increases (decreases) in cash caused by changes in operating assets and liabilities 1,169 (1,203) Increases (decreases) in cash caused by changes in operating assets and liabilities 1,169 (1,203) Other current assets 1,16	Cash flows used in operating activities:			<u> </u>	
Depreciation and amortization 366 896 Amortization of deferred financing costs and debt discount 584 550 In process research and development acquired from NanoTx Therapeutics 781 — Change in fair value of liability instruments (2,400) (3,407) Share-based compensation expense 247 127 Inventory write off 107 — Noncash lease expense 3 12 Loss on sale of business — 6,508 Allocation of issuance cost associated with warrants — 6,508 Accounts receivable 1,169 (1,203) Inventories — 259 Other current assets 126 (211) Other current assets 126 (211) Other assets 1,234 (28 Deferred revenue 9 (47) Other cash used in operating activities (8,43) (5,000 Cash flows from (used in) investing activities 9 (67) Proceads from year dequipment (93 (67) In process research and	Net loss	\$	(8,241)	\$	(10,887)
Amortization of deferred financing costs and debt discount 584 550 In process research and development acquired from NanoTx Therapeutics 781 — Change in fair value of flability instruments (2,400) (3,407) Share-based compensation expense 247 127 Inventory write off 107 — Noncash lease expense 3 12 Loss on sale of business — 6,508 Allocation of issuance cost associated with warrants — 6,508 Increases (decreases) in cash caused by changes in operating assets and liabilities: — 2,23 Increases (decreases) in cash caused by changes in operating assets and liabilities: — 2,59 Other current assets 1,169 (1,203) Inventories 5 6 (211) Other current assets 1 26 (211) Other current assets 1,169 (1,203) Accounts payable and accrued expenses (1,234) (28) Deferred revenue — 29 Other long-term liabilities (8,434) (5,306)	Adjustments to reconcile net loss to net cash used in operating activities:				
In process research and development acquired from NanoTx Therapeutics 781 — Change in fair value of liability instruments (2,400) (3,407) Share-based compensation expense 247 127 Inventory write off 107 — Noncash lease expense 3 12 Loss on sale of business — 6,508 Allocation of issuance cost associated with warrants — 6,508 Allocation of reseases (decreases) in cash caused by changes in operating assets and liabilities: — 6,508 Accounts receivable 1,169 (1,203) Inventories — 259 Other current assets 126 (211) Other sasets 126 (211) Other sasets 6 25 Accounts payable and accrued expenses (1,234) (28 Other Incy-term liabilities — 47 Net cash used in operating activities (407) 6,507 Other long-term (used in) investing activities (407) 6,537 Proceeds from sale of business (407) 6,537	Depreciation and amortization		366		896
Change in fair value of liability instruments (2,400) (3,407) Share-based compensation expense 247 127 Inventory write off 107 1-27 Noncash lease expense 3 12 Loss on sale of business - 6,508 Allocation of issuance cost associated with warrants - 1,233 Increases (decreases) in cash caused by changes in operating assets and liabilities: 1,169 (1,203) Inventories 1,66 (211) Other current assets 126 (211) Other current assets 158 263 Accounts payable and accrued expenses (1,234) (28 Deferred revenue - 29 Other long-term liabilities - (47) Net cash used in operating activities - (47) Net cash used in investing activities - (5,307) Cash flows from (used in) investing activities - 5,637 Proceeds from sale of business - 5,637 Net cash provided by (used in) investing activities - 5,637 <	Amortization of deferred financing costs and debt discount		584		550
Share-based compensation expense 247 127 Inventory write off 107 — Noncash lease expense 3 122 Loss on sale of business — 6,508 Allocation of issuance cost associated with warrants — 1,233 Increases (decreases) in cash caused by changes in operating assets and liabilities: — 259 Accounts receivable 1,169 (1,203) Inventories — 259 Other current assets 58 263 Accounts payable and accrued expenses (1,234) (28) Deferred revenue — 29 Other long-term liabilities — (47) Net cash used in operating activities — (47) Net cash used in operating activities — (47) Purchases of property and equipment (93) (67) In process research and development acquired from NanoTx Therapeutics (400) — Proceeds from sale of business — 5,637 Net cash provided by (used in) investing activities — 5,637	In process research and development acquired from NanoTx Therapeutics		781		_
Inventory write off	Change in fair value of liability instruments		(2,400)		(3,407)
Noncash lease expense 3 12 Loss on sale of business — 6,508 Allocation of issuance cost associated with warrants — 1,233 Increases (decreases) in cash caused by changes in operating assets and liabilities: — 259 Accounts receivable 1,169 (1,203) Inventories — 259 Other current assets 126 (211) Other current assets 58 263 Accounts payable and accrued expenses (1,234) (28 Deferred revenue — 29 Other long-term liabilities — 4(72) Net cash used in operating activities — (472) Purchases of property and equipment (93 (5,906) Purchases of property and equipment acquired from NanoTx Therapeutics (400) — Proceeds from sale of business — 5,637 Net cash provided by (used in) investing activities — 5,637 Cash flows from financing activities — 5,637 Principal payments of long-term obligations (5,007)	Share-based compensation expense		247		127
Loss on sale of business — 6,508 Allocation of issuance cost associated with warrants — 1,233 Increases (decreases) in cash caused by changes in operating assets and liabilities: — 2,000 Accounts receivable 1,169 (1,203) Inventories — 259 Other current assets 126 (211) Other assets (1,234) (28) Accounts payable and accrued expenses (1,234) (28) Deferred revenue — 47 Other long-term liabilities — (47) Net cash used in operating activities — (47) Net cash used in investing activities: — (400) Process research and development acquired from NanoTx Therapeutics (400) — Proceeds from sale of business — 5,637 Net cash provided by (used in) investing activities — 5,637 Principal payments of long-term obligations (5,307) (3,692) Payment of financing lease liability (117) (1311) Proceeds from sale of common stock 4	Inventory write off		107		_
Allocation of issuance cost associated with warrants 1,233 Increases (decreases) in cash caused by changes in operating assets and liabilities: 1,169 (1,203) Accounts receivable 1,169 (1,203) Inventories - 259 Other current assets 126 (211) Other assets 58 263 Accounts payable and accrued expenses (1,234) (28) Deferred revenue - 29 Other long-term liabilities - (47) Net cash used in operating activities (8,434) (5,906) Cash flows from (used in) investing activities: - (47) Purchases of property and equipment (93) (67) In process research and development acquired from NanoTx Therapeutics (400) - Proceeds from sale of business (403) 5,570 Net cash provided by (used in) investing activities (403) 5,570 Cash flows from financing activities: - (5,307) (3,682) Principal payments of long-term obligations (5,307) (3,682) Payment	Noncash lease expense		3		12
Increases (decreases) in cash caused by changes in operating assets and liabilities: 1,169 (1,203) Accounts receivable 1,169 (1,203) Inventories 259 259 Other current assets 58 263 Accounts payable and accrued expenses (1,234) (28) Deferred revenue - 29 Other long-term liabilities - (47) Net cash used in operating activities (8,434) (5,906) Cash flows from (used in) investing activities: (93) (67) Purchases of property and equipment (93) (67) In process research and development acquired from NanoTx Therapeutics (400) - Proceeds from sale of business - 5,637 Net cash provided by (used in) investing activities (493) 5,570 Cash flows from financing activities: - 5,637 Principal payments of long-term obligations (5,307) (3,692) Payment of financing lease liability (117) (131) Proceeds from sale of common stock 4,007 15,964 Ne	Loss on sale of business		_		6,508
Accounts receivable 1,169 (1,203) Inventories — 259 Other current assets 126 (211) Other assets 58 263 Accounts payable and accrued expenses (1,234) (28) Deferred revenue — 29 Other long-term liabilities — (47) Net cash used in operating activities — (47) Purchases of property and equipment (93) (67) In process research and development acquired from NanoTx Therapeutics (400) — Proceeds from sale of business — 5,637 Net cash provided by (used in) investing activities — 5,637 Principal payments of long-term obligations (5,307) (3,692) Payment of financing activities: — 1,098 490 Proceeds from exercise of warrants 1,098 490 Proceeds from exercise of warrants 4,007 15,964 Net cash (used in) provided by financing activities — (4) Proceeds from sale of common stock 4,007 15,964	Allocation of issuance cost associated with warrants		_		1,233
Inventories — 259 Other current assets 126 (211) Other assets 58 263 Accounts payable and accrued expenses (1,234) (288) Deferred revenue — 29 Other long-term liabilities — (47) Net cash used in operating activities — (47) Purchases of property and equipment (93) (67) In process research and development acquired from NanoTx Therapeutics (400) — Proceeds from sale of business — 5,637 Net cash provided by (used in) investing activities — 5,637 Principal payments of long-term obligations (5,307) (3,692) Payment of financing lease liability (117) (131) Proceeds from exercise of warrants (5,307) (3,692) Proceeds from sale of common stock (4,007) 15,964 Net cash (used in) provided by financing activities (31) 12,631 Effect of exchange rate changes on cash and cash equivalents (9,246) 12,291 Oke tash (used in) provided by financ	Increases (decreases) in cash caused by changes in operating assets and liabilities:				
Other current assets 126 (211) Other assets 58 263 Accounts payable and accrued expenses (1,234) (28) Deferred revenue — 29 Other long-term liabilities — (47) Net cash used in operating activities (8,434) (5,906) Cash flows from (used in) investing activities: Purchases of property and equipment (93) (67) In process research and development acquired from NanoTx Therapeutics (400) — Proceeds from sale of business — 5,637 Net cash provided by (used in) investing activities (493) 5,570 Cash flows from financing activities: Principal payments of long-term obligations (5,307) (3,692) Payment of financing lease liability (117) (131) Proceeds from exercise of warrants 1,098 490 Proceeds from sale of common stock 4,007 15,964 Net cash (used in) provided by financing activities (319) 12,631 Effect of exchange rate changes on cash and cash equivalents (9,246	Accounts receivable		1,169		(1,203)
Other assets 58 263 Accounts payable and accrued expenses (1,234) (28) Deferred revenue — 29 Other long-term liabilities — (47) Net cash used in operating activities (8,434) (5,906) Cash flows from (used in) investing activities: — (8,434) (5,906) Purchases of property and equipment (93) (67) (10) — Proceeds from sale of business — 5,637 — 5,637 Net cash provided by (used in) investing activities — 5,637 — 5,637 Net cash provided by (used in) investing activities — 5,307 (3,692) — Principal payments of long-term obligations (5,307) (3,692) — — — — 1,011 — — — — 1,021 — — — — — — 1,022 — — — — — — — — — — — — —	Inventories		_		259
Accounts payable and accrued expenses (1,234) (28) Deferred revenue — 29 Other long-term liabilities — (47) Net cash used in operating activities (8,434) (5,906) Cash flows from (used in) investing activities: Purchases of property and equipment (93) (67) In process research and development acquired from NanoTx Therapeutics (400) — Proceeds from sale of business — 5,637 Net cash provided by (used in) investing activities (493) 5,570 Cash flows from financing activities: Principal payments of long-term obligations (5,307) (3,692) Payment of financing lease liability (117) (131) Proceeds from exercise of warrants 1,098 490 Proceeds from sale of common stock 4,007 15,964 Net cash (used in) provided by financing activities (319) 12,631 Effect of exchange rate changes on cash and cash equivalents — (4) Net increase (decrease) in cash and cash equivalents (9,246) 12,291	Other current assets		126		(211)
Deferred revenue — 29 Other long-term liabilities — (47) Net cash used in operating activities (8,434) (5,906) Cash flows from (used in) investing activities: Purchases of property and equipment (93) (67) In process research and development acquired from NanoTx Therapeutics (400) — Proceeds from sale of business — 5,637 Net cash provided by (used in) investing activities (493) 5,570 Cash flows from financing activities: The cash provided by functing activities (5,307) (3,692) Principal payments of long-term obligations (5,307) (3,692) Payment of financing lease liability (117) (131) Proceeds from exercise of warrants 1,098 490 Proceeds from sale of common stock 4,007 15,964 Net cash (used in) provided by financing activities (319) 12,631 Effect of exchange rate changes on cash and cash equivalents — (4) Net increase (decrease) in cash and cash equivalents (9,246) 12,291 Cash, cash equivalents, a	Other assets		58		263
Other long-term liabilities — (47) Net cash used in operating activities (8,434) (5,906) Cash flows from (used in) investing activities: Purchases of property and equipment (93) (67) In process research and development acquired from NanoTx Therapeutics (400) — Proceeds from sale of business — 5,637 Net cash provided by (used in) investing activities (493) 5,570 Cash flows from financing activities: Principal payments of long-term obligations (5,307) (3,692) Payment of financing lease liability (117) (131) Proceeds from exercise of warrants 1,098 490 Proceeds from sale of common stock 4,007 15,964 Net cash (used in) provided by financing activities (319) 12,631 Effect of exchange rate changes on cash and cash equivalents — (4) Net increase (decrease) in cash and cash equivalents (9,246) 12,291 Cash, cash equivalents, and restricted cash at beginning of period 17,592 5,301	Accounts payable and accrued expenses		(1,234)		(28)
Net cash used in operating activities (8,434) (5,906) Cash flows from (used in) investing activities: User of property and equipment (approximately of property and equipment (approximately of process research and development acquired from NanoTx Therapeutics (approximately of proceeds from sale of business (approximately of proceeds from sale of business (approximately of proceeds from sale of business (approximately of proceeds from financing activities: User of provided by (used in) investing activities Cash flows from financing activities: (493) 5,570 Principal payments of long-term obligations (5,307) (3,692) Payment of financing lease liability (117) (131) Proceeds from exercise of warrants (1,098) 490 Proceeds from sale of common stock (1,098) 4,007 15,964 Net cash (used in) provided by financing activities (319) 12,631 16,000 Effect of exchange rate changes on cash and cash equivalents (1,092) 12,291 12,291 Cash, cash equivalents, and restricted cash at beginning of period (17,592) 5,301	Deferred revenue		_		29
Cash flows from (used in) investing activities:Purchases of property and equipment(93)(67)In process research and development acquired from NanoTx Therapeutics(400)—Proceeds from sale of business—5,637Net cash provided by (used in) investing activities(493)5,570Cash flows from financing activities:Principal payments of long-term obligations(5,307)(3,692)Payment of financing lease liability(117)(131)Proceeds from exercise of warrants1,098490Proceeds from sale of common stock4,00715,964Net cash (used in) provided by financing activities(319)12,631Effect of exchange rate changes on cash and cash equivalents—(4)Net increase (decrease) in cash and cash equivalents(9,246)12,291Cash, cash equivalents, and restricted cash at beginning of period17,5925,301	Other long-term liabilities		<u> </u>		(47)
Purchases of property and equipment (93) (67) In process research and development acquired from NanoTx Therapeutics (400) — Proceeds from sale of business — 5,637 Net cash provided by (used in) investing activities (493) 5,570 Cash flows from financing activities: V V Principal payments of long-term obligations (5,307) (3,692) Payment of financing lease liability (117) (131) Proceeds from exercise of warrants 1,098 490 Proceeds from sale of common stock 4,007 15,964 Net cash (used in) provided by financing activities (319) 12,631 Effect of exchange rate changes on cash and cash equivalents — (4) Net increase (decrease) in cash and cash equivalents (9,246) 12,291 Cash, cash equivalents, and restricted cash at beginning of period 17,592 5,301	Net cash used in operating activities		(8,434)		(5,906)
In process research and development acquired from NanoTx Therapeutics	Cash flows from (used in) investing activities:				
Proceeds from sale of business—5,637Net cash provided by (used in) investing activities(493)5,570Cash flows from financing activities:Principal payments of long-term obligations(5,307)(3,692)Payment of financing lease liability(117)(131)Proceeds from exercise of warrants1,098490Proceeds from sale of common stock4,00715,964Net cash (used in) provided by financing activities(319)12,631Effect of exchange rate changes on cash and cash equivalents—(4)Net increase (decrease) in cash and cash equivalents(9,246)12,291Cash, cash equivalents, and restricted cash at beginning of period17,5925,301	Purchases of property and equipment		(93)		(67)
Net cash provided by (used in) investing activities(493)5,570Cash flows from financing activities:Principal payments of long-term obligations(5,307)(3,692)Payment of financing lease liability(117)(131)Proceeds from exercise of warrants1,098490Proceeds from sale of common stock4,00715,964Net cash (used in) provided by financing activities(319)12,631Effect of exchange rate changes on cash and cash equivalents—(4)Net increase (decrease) in cash and cash equivalents(9,246)12,291Cash, cash equivalents, and restricted cash at beginning of period17,5925,301	In process research and development acquired from NanoTx Therapeutics		(400)		_
Cash flows from financing activities:Principal payments of long-term obligations(5,307)(3,692)Payment of financing lease liability(117)(131)Proceeds from exercise of warrants1,098490Proceeds from sale of common stock4,00715,964Net cash (used in) provided by financing activities(319)12,631Effect of exchange rate changes on cash and cash equivalents—(4)Net increase (decrease) in cash and cash equivalents(9,246)12,291Cash, cash equivalents, and restricted cash at beginning of period17,5925,301	Proceeds from sale of business		_		5,637
Principal payments of long-term obligations(5,307)(3,692)Payment of financing lease liability(117)(131)Proceeds from exercise of warrants1,098490Proceeds from sale of common stock4,00715,964Net cash (used in) provided by financing activities(319)12,631Effect of exchange rate changes on cash and cash equivalents—(4)Net increase (decrease) in cash and cash equivalents(9,246)12,291Cash, cash equivalents, and restricted cash at beginning of period17,5925,301	Net cash provided by (used in) investing activities		(493)		5,570
Payment of financing lease liability (117) (131) Proceeds from exercise of warrants 1,098 490 Proceeds from sale of common stock 4,007 15,964 Net cash (used in) provided by financing activities (319) 12,631 Effect of exchange rate changes on cash and cash equivalents — (4) Net increase (decrease) in cash and cash equivalents (9,246) 12,291 Cash, cash equivalents, and restricted cash at beginning of period 17,592 5,301	Cash flows from financing activities:				
Proceeds from exercise of warrants1,098490Proceeds from sale of common stock4,00715,964Net cash (used in) provided by financing activities(319)12,631Effect of exchange rate changes on cash and cash equivalents—(4)Net increase (decrease) in cash and cash equivalents(9,246)12,291Cash, cash equivalents, and restricted cash at beginning of period17,5925,301	Principal payments of long-term obligations		(5,307)		(3,692)
Proceeds from sale of common stock4,00715,964Net cash (used in) provided by financing activities(319)12,631Effect of exchange rate changes on cash and cash equivalents—(4)Net increase (decrease) in cash and cash equivalents(9,246)12,291Cash, cash equivalents, and restricted cash at beginning of period17,5925,301	Payment of financing lease liability		(117)		(131)
Net cash (used in) provided by financing activities Effect of exchange rate changes on cash and cash equivalents Net increase (decrease) in cash and cash equivalents Cash, cash equivalents, and restricted cash at beginning of period (319) 12,631 (4) 12,291 17,592 5,301	Proceeds from exercise of warrants		1,098		490
Effect of exchange rate changes on cash and cash equivalents Net increase (decrease) in cash and cash equivalents Cash, cash equivalents, and restricted cash at beginning of period 17,592 5,301	Proceeds from sale of common stock		4,007		15,964
Net increase (decrease) in cash and cash equivalents (9,246) 12,291 Cash, cash equivalents, and restricted cash at beginning of period 17,592 5,301	Net cash (used in) provided by financing activities		(319)		12,631
Net increase (decrease) in cash and cash equivalents (9,246) 12,291 Cash, cash equivalents, and restricted cash at beginning of period 17,592 5,301	Effect of exchange rate changes on cash and cash equivalents				(4)
Cash, cash equivalents, and restricted cash at beginning of period 17,592 5,301	Net increase (decrease) in cash and cash equivalents		(9,246)		
	,		, ,		•
		\$	8,346	\$	17,592

Supplemental disclosure of cash flows information: Cash paid during period for: Interest \$ 567 1,188 Supplemental schedule of non-cash investing and financing activities: Issuance costs paid in common stock \$ 463 \$ Common stock issued in payment for in process research and development \$ 381 \$ Unpaid offering cost 125 \$ Proceeds from sales of business, net, paid directly to lender for principal payment of long-term obligations \$ \$ 3,050 \$ Offering cost paid in warrants 213 Reclassification of warrants upon exercise from liability to equity \$ 4,504 \$ 794 Fair value of Convertible Preferred Stock beneficial conversion feature \$ \$ 554

Investor Contact

Peter Vozzo Westwicke/ICR (443) 377-4767 Peter Vozzo@westwicke.com

Media Contact

Terri Clevenger Westwicke/ICR (203) 856-4326 Terri.Clevenger@westwicke.com



Source: Plus Therapeutics Inc.